Industry experts are raising concerns about the potential economic impact of proposed tariffs on pharmaceutical imports from India. The chief executive of a major Indian generic drug manufacturer has cautioned that increased levies could significantly inflate medication costs for American consumers. This development highlights the delicate balance between trade policy and healthcare affordability, as generic drugs remain a critical component of accessible healthcare for millions of patients across the United States.

Summary auto-generated by AI from the original publisher's content. Editorial standards.